The Role of Aspirin, Vitamin D, Exercise, Diet, Statins, and Metformin in the Prevention and Treatment of Colorectal Cancer

Current Treatment Options in Oncology

Volumn 16, Issue 9, 2015, Pages

  Sehdev, Amikar ^a   O’Neil, Bert H ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Aspirin; Celecoxib; Colorectal cancer; Diet; Metformin; NSAIDS; Physical activity; Statins; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ACETYLSALICYLIC ACID; BEVACIZUMAB; BUTYRIC ACID; CALCIUM; CAPECITABINE; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; FLUOROURACIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; OXALIPLATIN; ROFECOXIB; SIMVASTATIN; VITAMIN D; 25-HYDROXYVITAMIN D; ANTIDIABETIC AGENT;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; COLON ADENOMA; COLORECTAL ADENOMA; COLORECTAL CANCER; DIET THERAPY; DRUG MECHANISM; EXERCISE; EXERCISE INTENSITY; FAMILIAL COLON POLYPOSIS; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HIGH FIBER DIET; HIGH RISK POPULATION; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOPARATHYROIDISM; LIFESTYLE MODIFICATION; LOW DRUG DOSE; LOW FAT DIET; NEPHROLITHIASIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW (TOPIC); VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; CHEMOPROPHYLAXIS; COLORECTAL NEOPLASMS; DIET; OBSERVATIONAL STUDY; RISK ASSESSMENT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CHEMOPREVENTION; COLORECTAL NEOPLASMS; DIET; EXERCISE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; METFORMIN; OBSERVATIONAL STUDIES AS TOPIC; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; VITAMIN D;

EID: 84938081688     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-015-0359-z     Document Type: Article

References (173)

1. Jemal A et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
2. Flossmann E et al. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369(9573):1603–13.
3. Rothwell PM et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741–50.
4. Rothwell PM et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31–41.
5. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 1988;48(15):4399–404.
6. Dube C et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007;146(5):365–75.
7. Rostom A et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007;146(5):376–89.
8. Cole BF et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009;101(4):256–66.
9. Burn J et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378(9809):2081–7.
10. Cook NR et al. Low-dose aspirin in the primary prevention of cancer the women’s health study: a randomized controlled trial. JAMA J Am Med Assoc. 2005;294(1):47–55.
11. Ridker PM et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293–304.
12. Sung JJ. Is aspirin for colorectal cancer prevention on the prime time yet? Gut. 2014;63(11):1691–2. Concise review and perspective on role of aspirin in colorectal cancer prevention highlighting major issues and their limitations.
13. Cook NR et al. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013;159(2):77–85. This study reported on the 10 years observational follow-up of the Womens Health Study (a randomized trial) showing benefit of 100 mg alternate-day dosing in colorectal cancer risk reduction in healthy women.
14. Steinbach G et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342(26):1946–52.
15. Higuchi T et al. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res. 2003;9(13):4756–60.
16. Bertagnolli MM et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355(9):873–84.
17. Arber N et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355(9):885–95.
18. Solomon SD et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008;117(16):2104–13.
19. Bertagnolli MM et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila). 2009;2(4):310–21.
20. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol. 2012;9(5):259–67. An extensive review describing the current evidence in support of beneficial effect of aspirin and COX-2 inhibitors. The review also discusses potential adverse effects and mechanism of action of aspirin in great detail.
21. Liao X, Lochhead P, Nishihara R. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367(17):1596–606. A retrospective analysis that showed higher CRC-specific survival among aspirin-using patients with mutated-PIK3CA tumors as compared to wild type-PIK3CA tumors.
22. Dougherty U et al. Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model. Clin Cancer Res. 2008;14(8):2253–62.
23. Chan AT, Fuchs CS, Ogino S. Aspirin use and survival after diagnosis of colorectal cancer. Gastroenterology. 2009;136(5):A55.
24. Kothari N et al. Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. Acta Oncol. 2015;54(4):487–92. A subsequent study assessing the CRC-specific survival in patients with mutated-PIK3CA tumors versus wild-type tumors showing no survival benefit.
25. Nan H et al. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA. 2015;313(11):1133–42. A case-control study reporting the protective effect of aspirin to be highly correlated with two single-nucleotide polymorphisms (rs2965667 and rs10505806) found in 96% of the population.
26. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol. 1980;9(3):227–31.
27. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer. 1992;70(12):2861–9.
28. Li MA et al. Review: the impacts of circulating 25-Hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99(7):2327–36. A meta-analysis 25 studies with 17,332 patients reporting a positive association between circulating 25(OH)D levels at diagnosis and cancer outcomes.
29. Ma YL et al. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol. 2011;29(28):3775–82.
30. Feskanich D et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomark Prev. 2004;13(9):1502–8.
31. Otani T et al. Plasma vitamin D and risk of colorectal cancer: the Japan Public Health Center-based prospective study. Br J Cancer. 2007;97(3):446–51.
32. Woolcott CG et al. Plasma 25-hydroxyvitamin D levels and the risk of colorectal cancer: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev. 2010;19(1):130–4.
33. Wu K et al. A nested case-control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. J Natl Cancer Inst. 2007;99(14):1120–9.
34. Weinstein SJ et al. Serum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer. 2015;136(6):E654–64. A prospective study of serum 25(OH)D and vitamin D binding protein concentrations and CRC risk in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial reporting a higher vitamin D level is associated with lower risk of CRC.
35. Ishihara J et al. Dietary calcium, vitamin D, and the risk of colorectal cancer. Am J Clin Nutr. 2008;88(6):1576–83.
36. Lipworth L et al. Dietary Vitamin D intake and cancers of the colon and rectum: a case-control study in Italy. Nutr Cancer Int J. 2009;61(1):70–5.
37. Mizoue T et al. Calcium, dairy foods, vitamin D, and colorectal cancer risk: the Fukuoka colorectal cancer study. Cancer Epidemiol Biomark Prev. 2008;17(10):2800–7.
38. Terry P et al. Dietary calcium and vitamin D intake and risk of colorectal cancer: a prospective cohort study in women. Nutr Cancer Int J. 2002;43(1):39–46.
39. Theodoratou E et al. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ. 2014;348:g2035. An umbrella review (including meta-analyses and systematic review to assess the effect of vitamin D on cancer and other health problems) showing a beneficial effect of higher vitamin D level on CRC.
40. Touvier M et al. Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2011;20(5):1003–16.
41. Song M, Garrett WS, Chan AT. Nutrients, Foods, and Colorectal Cancer Prevention. Gastroenterology, 2015. A thorough review of current evidence for different dietary nutrients for the prevention of CRC.
42. LeBlanc ES et al. Screening for vitamin D deficiency: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2015;162(2):109–22. Guidelines based on current evidence for the diagnosis and treatment of vitamin D deficiency.
43. Gorham ED et al. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med. 2007;32(3):210–6.
44. Wactawski-Wende J et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med. 2006;354(7):684–96.
45. Bolland MJ et al. Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women’s Health Initiative (WHI) limited-access data set. Am J Clin Nutr. 2011;94(4):1144–9.
46. Chlebowski RT, Pettinger M, Kooperberg C. Caution in reinterpreting the Women’s Health Initiative (WHI) Calcium and Vitamin D Trial breast cancer results. Am J Clin Nutr. 2012;95(1):258–9. author reply 259.
47. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007;7(9):684–700.
48. Feldman D et al. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014;14(5):342–57. An extensive review on the epidemiological, preclinical and clinical studies assessing the role of vitamin D in cancer prevention and the potential mechanisms for the same.
49. Bischoff-Ferrari HA et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84(1):18–28.
50. Ng K et al. Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial(1-4). Am J Clin Nutr. 2014;99(3):587–98. A randomized trial to assess the dose-response relationship between vitamin D3 intake and recommended plasma 25(OH)D level for cancer prevention in African American population.
51. Garland CF et al. Vitamin D for cancer prevention: global perspective. Ann Epidemiol. 2009;19(7):468–83.
52. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Ross AC, Taylor CL, Yaktine AL, et al., editors. Dietary Reference Intakes for Calcium and Vitamin D. Washington (DC): National Academies Press (US); 2011. http://www.ncbi.nlm.nih.gov/books/NBK56070/.
53. LeBlanc E, et al. Screening for Vitamin D Deficiency: Systematic Review for the U.S. Preventive Services Task Force Recommendation. Evidence Synthesis No. 119. AHRQ Publication No. 13-05183-EF-1. Rockville (MD): Agency for Healthcare Research and Quality; 2014. A systematic review and proposed guidelines for the treatment of vitamin D deficiency in asymptomatic adults
54. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008;88(2):582S–6.
55. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr. 1999;69(5):842–56.
56. Wolin KY, Tuchman H. Physical activity and gastrointestinal cancer prevention. Recent Results Cancer Res. 2011;186:73–100.
57. Giovannucci E et al. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med. 1995;122(5):327–34.
58. Isomura K et al. Physical activity and colorectal cancer: the Fukuoka Colorectal Cancer Study. Cancer Sci. 2006;97(10):1099–104.
59. Howard RA et al. Physical activity, sedentary behavior, and the risk of colon and rectal cancer in the NIH-AARP Diet and Health Study. Cancer Causes Control. 2008;19(9):939–53.
60. Boyle T et al. Timing and intensity of recreational physical activity and the risk of subsite-specific colorectal cancer. Cancer Causes Control. 2011;22(12):1647–58.
61. Boyle T et al. Physical activity and risks of proximal and distal colon cancers: a systematic review and meta-analysis. J Natl Cancer Inst. 2012;104(20):1548–61. A systematic review and meta-analysis of 21 studies showing a protective effect of physical activity proximal as well as distal CRC.
62. Allgayer H, Nicolaus S, Schreiber S. Decreased interleukin-1 receptor antagonist response following moderate exercise in patients with colorectal carcinoma after primary treatment. Cancer Detect Prev. 2004;28(3):208–13.
63. Allgayer H et al. Short-term moderate exercise programs reduce oxidative DNA damage as determined by high-performance liquid chromatography-electrospray ionization-mass spectrometry in patients with colorectal carcinoma following primary treatment. Scand J Gastroenterol. 2008;43(8):971–8.
64. Bourke L et al. Pragmatic lifestyle intervention in patients recovering from colon cancer: a randomized controlled pilot study. Arch Phys Med Rehabil. 2011;92(5):749–55.
65. Courneya KS et al. A randomized trial of exercise and quality of life in colorectal cancer survivors. Eur J Cancer Care (Engl). 2003;12(4):347–57.
66. Pinto BM et al. Home-based physical activity intervention for colorectal cancer survivors. Psychooncology. 2013;22(1):54–64.
67. Cramer H et al. A systematic review and meta-analysis of exercise interventions for colorectal cancer patients. Eur J Cancer Care (Engl). 2014;23(1):3–14. A systematic review and meta-analysis of 5 randomized controlled studies showing a no short-term effects of exercise on quality of life or fatigue however there was beneficial effect on physical fitness.
68. Je Y et al. Association between physical activity and mortality in colorectal cancer: a meta-analysis of prospective cohort studies. Int J Cancer. 2013;133(8):1905–13. A meta-analysis of prospective cohort studies showing a decreased relative risk for CRC in patients who were physically active before the diagnosis as well as decreased CRC-specific mortality in patients who continued to be physically active post-diagnosis.
69. Arem H et al. Pre- and postdiagnosis physical activity, television viewing, and mortality among patients with colorectal cancer in the National Institutes of Health-AARP Diet and Health Study. J Clin Oncol. 2015;33(2):180–8. A study reporting an inverse association between the overall and disease-specific mortality and leisure time physical activity before and after the CRC diagnosis.
70. Meyerhardt JA et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2006;24(22):3535–41.
71. Basterfield L, Reul JM, Mathers JC. Impact of physical activity on intestinal cancer development in mice. J Nutr. 2005;135(12 Suppl):3002S–8.
72. Ju J et al. Voluntary exercise inhibits intestinal tumorigenesis in Apc(Min/+) mice and azoxymethane/dextran sulfate sodium-treated mice. BMC Cancer. 2008;8:316.
73. Burkitt DP. Epidemiology of cancer of the colon and rectum. Cancer. 1971;28(1):3–13.
74. Kritchevsky D. Epidemiology of fibre, resistant starch and colorectal cancer. Eur J Cancer Prev. 1995;4(5):345–52.
75. Hamer HM et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008;27(2):104–19.
76. Fung KY et al. A review of the potential mechanisms for the lowering of colorectal oncogenesis by butyrate. Br J Nutr. 2012;108(5):820–31.
77. Peters U et al. Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme. Lancet. 2003;361(9368):1491–5.
78. Bingham SA et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet. 2003;361(9368):1496–501.
79. Larsson SC et al. Whole grain consumption and risk of colorectal cancer: a population-based cohort of 60,000 women. Br J Cancer. 2005;92(9):1803–7.
80. Park Y et al. Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. JAMA. 2005;294(22):2849–57.
81. Alberts DS et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians’ Network. N Engl J Med. 2000;342(16):1156–62.
82. Schatzkin A et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med. 2000;342(16):1149–55.
83. McKeown-Eyssen GE et al. A randomized trial of a low fat high fibre diet in the recurrence of colorectal polyps. Toronto Polyp Prevention Group. J Clin Epidemiol. 1994;47(5):525–36.
84. MacLennan R et al. Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. J Natl Cancer Inst. 1995;87(23):1760–6.
85. Willett WC et al. Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med. 1990;323(24):1664–72.
86. Beresford SA et al. Low-fat dietary pattern and risk of colorectal cancer: the Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295(6):643–54.
87. Flood A et al. Meat, fat, and their subtypes as risk factors for colorectal cancer in a prospective cohort of women. Am J Epidemiol. 2003;158(1):59–68.
88. Jarvinen R et al. Dietary fat, cholesterol and colorectal cancer in a prospective study. Br J Cancer. 2001;85(3):357–61.
89. Lin J et al. Dietary fat and fatty acids and risk of colorectal cancer in women. Am J Epidemiol. 2004;160(10):1011–22.
90. Terry P et al. No association between fat and fatty acids intake and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2001;10(8):913–4.
91. Liu L et al. Is dietary fat associated with the risk of colorectal cancer? A meta-analysis of 13 prospective cohort studies. Eur J Nutr. 2011;50(3):173–84.
92. Pietinen P et al. Diet and risk of colorectal cancer in a cohort of Finnish men. Cancer Causes Control. 1999;10(5):387–96.
93. Norat T et al. Meat, fish, and colorectal cancer risk: the European Prospective Investigation into cancer and nutrition. J Natl Cancer Inst. 2005;97(12):906–16.
94. Kampman E et al. Vegetable and animal products as determinants of colon cancer risk in Dutch men and women. Cancer Causes Control. 1995;6(3):225–34.
95. Wu S et al. Fish consumption and colorectal cancer risk in humans: a systematic review and meta-analysis. Am J Med. 2012;125(6):551–9 e5. A meta-analysis of twenty-two prospective cohort and 19 case-control studies reporting a significant inverse association between fish consumption and the risk of CRC.
96. West NJ et al. Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut. 2010;59(7):918–25.
97. Dougherty U et al. Epidermal growth factor receptor is required for colonic tumor promotion by dietary fat in the azoxymethane/dextran sulfate sodium model: roles of transforming growth factor-{alpha} and PTGS2. Clin Cancer Res. 2009;15(22):6780–9.
98. Lindner MA. A fish oil diet inhibits colon cancer in mice. Nutr Cancer. 1991;15(1):1–11.
99. Singh J, Hamid R, Reddy BS. Dietary fat and colon cancer: modulating effect of types and amount of dietary fat on ras-p21 function during promotion and progression stages of colon cancer. Cancer Res. 1997;57(2):253–8.
100. Takahashi M et al. Suppression of azoxymethane-induced rat colon carcinoma development by a fish oil component, docosahexaenoic acid (DHA). Carcinogenesis. 1997;18(7):1337–42.
101. Chapkin RS et al. Mechanisms by which docosahexaenoic acid and related fatty acids reduce colon cancer risk and inflammatory disorders of the intestine. Chem Phys Lipids. 2008;153(1):14–23.
102. Wu K et al. Calcium intake and risk of colon cancer in women and men. J Natl Cancer Inst. 2002;94(6):437–46.
103. Shaukat A, Scouras N, Schunemann HJ. Role of supplemental calcium in the recurrence of colorectal adenomas: a metaanalysis of randomized controlled trials. Am J Gastroenterol. 2005;100(2):390–4.
104. Martinez ME, Jacobs ET. Calcium supplementation and prevention of colorectal neoplasia: lessons from clinical trials. J Natl Cancer Inst. 2007;99(2):99–100.
105. Keum N et al. Calcium intake and colorectal cancer risk: dose-response meta-analysis of prospective observational studies. Int J Cancer. 2014;135(8):1940–8. A meta-analysis showing an inverse relationship between the dietary as well as supplemental calcium intake and CRC risk based on prospective observational studies.
106. Newmark HL, Wargovich MJ, Bruce WR. Colon cancer and dietary fat, phosphate, and calcium: a hypothesis. J Natl Cancer Inst. 1984;72(6):1323–5.
107. Lamprecht SA, Lipkin M. Cellular mechanisms of calcium and vitamin D in the inhibition of colorectal carcinogenesis. Ann N Y Acad Sci. 2001;952:73–87.
108. Fedirko V et al. Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2010;19(1):280–91.
109. Lochhead P, Chan AT. Statins and colorectal cancer. Clin Gastroenterol Hepatol. 2013;11(2):109–18. A thorough review on the current evidence, mechanism of action, adverse effects, and future potential of statins in CRC prevention.
110. Katz MS. Therapy insight: potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol. 2005;2(2):82–9.
111. Demierre M-F et al. Statins and cancer prevention. Nat Rev Cancer. 2005;5(12):930–42.
112. Poynter JN et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352(21):2184–92.
113. Broughton T, Sington J, Beales IL. Statin use is associated with a reduced incidence of colorectal cancer: a colonoscopy-controlled case–control study. BMC Gastroenterol. 2012;12(1):1.
114. Lakha F et al. Statin use and association with colorectal cancer survival and risk: case control study with prescription data linkage. BMC Cancer. 2012;12:487.
115. Sehdev A et al. The role of statins for primary prevention in non-elderly colorectal cancer patients. Anticancer Res. 2014;34(9):5043–50. This is the largest case-control study of statins in non-elderly (age <65 years) US population reporting a 26% reduced odds of developing CRC with statin intake.
116. Blais L, Desgagné A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med. 2000;160:2363–8.
117. Graaf MR. The risk of cancer in users of statins. J Clin Oncol. 2004;22(12):2388–94.
118. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer. 2004;90(3):635–7.
119. Vinogradova Y et al. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology. 2007;133(2):393–402.
120. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology. 2007;18:213–9.
121. Coogan PF, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. JNCI J Natl Cancer Inst. 2007;99(1):32–40.
122. Yang Y-X et al. Chronic statin therapy and the risk of colorectal cancer. Pharmacoepidemiol Drug Saf. 2008;17(9):869–76.
123. Boudreau DM, et al. Cardiovascular medication use and risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev Publ Am Assoc Cancer Res, cosponsored by the American Society of Preventive Oncology, 2008;17(11):3076–80.
124. Shadman M et al. Non-steroidal anti-inflammatory drugs and statins in relation to colorectal cancer risk. World J Gastroenterol. 2009;15(19):2336–9.
125. Robertson DJ et al. Neither long-term statin use nor atherosclerotic disease is associated with risk of colorectal cancer. Clin Gastroenterol Hepatol. 2010;8(12):1056–61.
126. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer. 2011;11(1):409.
127. Cheng M-H. Statin use and the risk of colorectal cancer: a population-based case-control study. World J Gastroenterol. 2011;17(47):5197.
128. Lee JE et al. Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev Res. 2011;4(11):1808–15.
129. Simon MS, Rosenberg CA, Rodabough RJ. Prospective analysis of association between use of statins or other lipid-lowering agents and colorectal cancer risk. Ann Epidemiol. 2012;22:17–27. A prospective analyses of 1,59,219 postmenopausal women of the Women’s Health Initiative cohort found a significantly reduced risk of CRC with the use of lovastatin.
130. Jacobs EJ, Rodriguez C, Brady KA. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst. 2006;98:69–72.
131. Friedman GD et al. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf. 2008;17(1):27–36.
132. Setoguchi S et al. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation. 2006;115(1):27–33.
133. Singh H et al. Long-term use of statins and risk of colorectal cancer: a population-based study. Am J Gastroenterol. 2009;104:3015–23.
134. Flick ED et al. Statin use and risk of colorectal cancer in a cohort of middle-aged men in the US: a prospective cohort study. Drugs. 2009;69(11):1445–57.
135. Haukka J et al. Incidence of cancer and statin usage-record linkage study. International journal of cancer. J Int Cancer. 2010;126(1):279–84.
136. Jacobs EJ et al. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res. 2011;71(5):1763–71.
137. Friis S et al. Cancer risk among statin users: a population-based cohort study. International journal of cancer. J Int Cancer. 2005;114(4):643–7.
138. Sacks FM, Pfeffer MA, Moye LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–9.
139. Downs JR et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA J Am Med Assoc. 1998;279(20):1615–22.
140. L.S.G.L.-t.I.w.P.i.I. Disease. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet. 2002;359(9315):1379–87.
141. Trial, A.O.a.C.f.t.A.C.R.G.T.A.a.L.-L.T.t.P.H.A. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA J Am Med Assoc. 2002;288(23):2998–3007.
142. Strandberg TE et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2004;364(9436):771–7.
143. Group HPSC. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Med. 2005;3:6.
144. Ford I et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med. 2007;357(15):1477–86.
145. Hsia J et al. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. J Am Coll Cardiol. 2011;57(16):1666–75.
146. Baigent C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–92.
147. Bonovas S et al. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol. 2007;25(23):3462–8.
148. Bardou M, Barkun A, Martel M. Effect of statin therapy on colorectal cancer. Gut. 2010;59:1572–85.
149. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov. 2007;6(7):541–55.
150. Lee J et al. Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. Investig New Drugs. 2014;32(3):535–41. A phase II clinical trial of treatment with cetuximab and irinotecan in patients with KRAS mutant tumors showing an improvement in median PFS and median OS compared to historical controls.
151. Krens LL et al. Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study. PLoS One. 2014;9(11):e112201. A retrospective analysis of the phase III CAIRO2 study showing no significant improvement in either median PFS or median OS in patients with KRAS mutant tumors who were on statin therapy in addition to chemotherapy.
152. Tomimoto A et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci. 2008;99(11):2136–41.
153. Hosono K et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog. 2010;49(7):662–71.
154. Vigneri P et al. Diabetes and cancer. Endocr Relat Cancer. 2009;16(4):1103–23.
155. Giovannucci E et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–85.
156. Lee MS et al. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011;11:20.
157. Libby G et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32(9):1620–5.
158. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52(9):1766–77.
159. Garrett CR et al. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer. 2012;106(8):1374–8.
160. Jiralerspong S et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27(20):3297–302.
161. Sehdev A. et al. Metformin for primary colorectal cancer prevention in patients with diabetes: A case-control study in a US population. Cancer. 2015;121(7):1071–8. A large case-control study in diabetic United States population showing reduced odds of developing CRC among metformin users as compared to non-users.
162. Korsse SE, Peppelenbosch MP, van Veelen W. Targeting LKB1 signaling in cancer. Biochim Biophys Acta. 2012;1835(2):194–210.
163. Hosono K et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila). 2010;3(9):1077–83.
164. Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2012;2(9):778–90.
165. Jalving M et al. Metformin: taking away the candy for cancer? Eur J Cancer. 2010;46(13):2369–80.
166. Pierotti MA. et al. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene. 2013;32(12):1475–87. An extensive review on the current evidence, mechanism of action and ongoing studies of metformin in prevention and treatment of cancer.
167. Rattan R, Ali Fehmi R, Munkarah A. Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis. J Oncol. 2012;2012:928127.
168. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med. 2006;119(8):624–38.
169. Tougeron D et al. Aspirin and colorectal cancer: back to the future. Clin Cancer Res. 2014;20(5):1087–94. A review on current evidence in support of aspirin for CRC prevention especially highlighting the role of potential molecular markers (such as, PIK3CA) in individualizing aspirin therapy.
170. Kim Y, Je Y. Dietary fiber intake and total mortality: a meta-analysis of prospective cohort studies. Am J Epidemiol. 2014;180(6):565–73. A pooled meta-analysis of seven propective cohort studies showing that a high dietary fiber intake may result in reduction of total mortality.
171. Threapleton DE et al. Dietary fibre intake and risk of cardiovascular disease: systematic review and meta-analysis. BMJ. 2013;347:f6879.
172. Hull MA et al. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial. Trials. 2013;14:237.
173. U.S. Department of Health and Human Services. Office of Disease Prevention and Health Promotion. Healthy People 2020. Washington, DC. Available at: http://www.healthypeople.gov/2020/topics-objectives/topic/physical-activity. Accessed 27 March 2015.